Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
Por:
Novick D, Montgomery W, Haro JM, Moneta MV, Zhu G, Yue L, Hong J, Dueñas H and Brugnoli R
Publicada:
23 feb 2016
Resumen:
To assess and compare the levels of functioning in patients with major depressive disorder treated with either duloxetine with a daily dose of =60 mg or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic setting in East Asia. In addition, this study examined the impact of painful physical symptoms (PPS) on the effects of these treatments.
Filiaciones:
Novick D:
Eli Lilly and Company, Windlesham, Surrey, UK
Montgomery W:
Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia
Haro JM:
Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain
Moneta MV:
Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain
Zhu G:
Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China
Yue L:
Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People's Republic of China
Hong J:
Department of Healthcare Management, Gachon University, Seongnam, South Korea
Dueñas H:
Eli Lilly de Mexico, Mexico City, Mexico
Brugnoli R:
School of Medicine, Sapienza University of Rome, Rome, Italy
Open Access
|